Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Thomas Heineman

Otolaryngology Cedar Rapids, IA Medical Doctor

NPI 1881089704 CMS profile 8762389

202 10Th St Se, Cedar Rapids, IA 52403

Open in the dashboard

General payments

$373,128

259 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Heineman of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $373,128 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $99,637 89
2024 General $129,441 89
2023 General $95,280 49
2022 General $46,890 14
2021 General $975 5
2020 General $905 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Heineman
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Thomas Heineman were reported at $99,637. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Thomas Heineman Otolaryngology median Middle half National median
2019 $0 $194 $82–$512 $163
2020 $905 $118 $42–$280 $114
2021 $975 $167 $63–$444 $132
2022 $46,890 $216 $84–$545 $149
2023 $95,280 $235 $93–$588 $160
2024 $129,441 $280 $111–$699 $164
2025 $99,637 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Inspire Medical Systems, Inc. $294,078 203 payments
  2. Siesta Medical, Inc. $60,900 4 payments
  3. Aerin Medical Inc. $15,426 21 payments
  4. Stryker Corporation $2,590 26 payments
  5. Respicardia, Inc. $50 1 payment
  6. KARL STORZ Endoscopy-America $33 1 payment
  7. Pfizer Inc. $23 1 payment
  8. ARS Pharmaceuticals Operations, Inc. $15 1 payment
  9. Biohaven Pharmaceutical Holding Company Ltd. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $302,664 48 payments
  2. Travel and Lodging $33,465 101 payments
  3. Honoraria $28,000 11 payments
  4. Food and Beverage $9,000 99 payments
Products named General payments · program years 2020–2025
  1. INSPIRE $255,647 197 payments
  2. Inspire Upper Airway Stimulation System $38,431 6 payments
  3. VIVAER STYLUS $15,426 21 payments
  4. SCOPIS ENT $1,096 6 payments
  5. RHINAER STYLUS $889 10 payments
  6. ENTELLUS - XPRESS ENT DILATION SYSTEM $388 5 payments
  7. CLARIFIX $226 5 payments
  8. FIAGON NAVIGATION UNIT $161 1 payment
  9. XPRESS ENT DILATION SYSTEM $158 3 payments
  10. MAKO $136 1 payment
  11. Other $742 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

430

Median for Otolaryngology: 297

Drug cost

$6,279

Median for Otolaryngology: $6,314

Branded share of claims

31.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 149 $4,851
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 89 $564
Cephalexin Generic 86 $370
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 29 $260
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $92
Omeprazole Generic 23 $84
Prednisone Generic 22 $51
Zolpidem Tartrate Generic 13 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$195,977

Of which drugs: $147

Medicare patients

505

Average age 73

Services billed

3,348

260 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 48%
Ischemic heart disease 26%
Depression 25%
Diabetes 22%
Chronic kidney disease 21%
Atrial fibrillation 17%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record